Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Lignende værker

• CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
  af: Chrisanthar, Ranjan, et al.
  Udgivet: (2008)
• Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
  af: Chrisanthar, Ranjan, et al.
  Udgivet: (2011)
• Prevalence of the CHEK2 R95* germline mutation
  af: Knappskog, Stian, et al.
  Udgivet: (2016)
• Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
  af: Knappskog, Stian, et al.
  Udgivet: (2015)
• Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
  af: Mathiesen, Randi R, et al.
  Udgivet: (2012)